DBT approves funding for three companies for developing COVID-19 vaccine

NEW DELHI: The Department of Biotechnology has so far short-listed three companies for funding the development of a vaccine for COVID-19, besides 13 other proposals it received for diagnostics, therapeutics and other interventions to fight coronavirus, a statement said.

The DBT said a multifaceted approach is being adopted to ensure that vaccine companies utilising different platforms and at different stages of development are fast tracked through a research consortium under funding from the National Biopharma Mission, an initiative launched in 2017 to support development of vaccines and drugs.

The Department of Biotechnology and the Biotechnology Industry Research Assistance Council had invited applications on the COVID-19 Research Consortium. The first phase of the call ended on March 30 and around 500 applications were received from academia and industry, the DBT said in a statement.

The multi-tiered review process is ongoing and till date 16 proposals of devices, diagnostics, vaccine candidates, therapeutics and other interventions have been recommended for receiving funding support, it said.

Both repurposing of existing vaccine companies for immediate protection of high-risk groups and novel vaccine candidate development were considered while selecting proposals under this call.

“Funding support has been recommended to Cadila Healthcare Ltd for advancing the development of a DNA Vaccine candidate against novel coronavirus SARS-CoV-2. and to Bharat Biotech International Ltd for COVID-19 vaccine candidate utilising the inactivated rabies vector platform.

“For the Phase III human clinical trials study of recombinant BCG vaccine planned in high-risk population, Serum Institute of India Private Limited (SIIPL) will be supported,” the statement said.

Source Article